Clinical Trial Update: An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy [Phase 2]

View source ↗

Summary

An extension study to evaluate long-term safety of lampalizumab in geographic atrophy participants; terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Geographic Atrophy

Drugs mentioned

• lampalizumab (lampalizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Geographic Atrophy | Phase 2 | Status: TERMINATED | Results posted: 2019-02-21